Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 45Sarcoma 33Lymphoma, Large B-Cell, Diffuse 32Neoplasms 25Lymphoma 20Lymphoma, Non-Hodgkin 19Ovarian Neoplasms 17Lymphoma, Follicular 16Neoplasm Metastasis 12Triple Negative Breast Neoplasms 11Lymphoma, B-Cell 11Endometrial Neoplasms 11Recurrence 10Carcinoma, Hepatocellular 8Hodgkin Disease 7Lymphoma, T-Cell, Peripheral 6Hematologic Diseases 6Sarcoma, Kaposi 5Lymphoma, Mantle-Cell 5Leiomyosarcoma 5HIV Infections 5Acquired Immunodeficiency Syndrome 5Multiple Myeloma 4Liposarcoma 4Small Cell Lung Carcinoma 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Lymphoma, B-Cell, Marginal Zone 3Liver Neoplasms 3Leukemia, Lymphocytic, Chronic, B-Cell 3Fallopian Tube Neoplasms 3

Interventions

dacetuzumab 6Rituximab 6blinatumomab 4ibrutinib 3Ifosfamide 3Bortezomib 3ponatinib 2cobomarsen 2Vorinostat 2Lenalidomide 2Etoposide 2Dexamethasone 2Carboplatin 2tetulomab tetraxetan lu-177 1pegaspargase 1ficlatuzumab 1enzalutamide 1durvalumab 1cirmtuzumab 1asparaginase erwinia chrysanthemi recombinant 1acalabrutinib 1Vincristine 1Prednisone 1Methotrexate 1Lutetium 1KW-2478 1Imatinib Mesylate 1Hsp90 inhibitor KU757 1Gemcitabine 1Erlotinib Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Immunoproliferative Disorders × Doxorubicin × Clear all
NCT02855359 2019-03-11

Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma

Seagen Inc.

Phase 2 Terminated
24 enrolled 10 charts
Lymphoid

Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms, Neoplasms by Histologic Type, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡